Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Pravastatin sodium |
EINECS | 1806241-263-5 |
CAS No. | 81131-70-6 | Density | N/A |
PSA | 124.29000 | LogP | 2.55290 |
Solubility | N/A | Melting Point |
171.2-173 °C |
Formula | C23H35NaO7 | Boiling Point | 634.5 °C at 760 mmHg |
Molecular Weight | 446.516 | Flash Point | 213.2 °C |
Transport Information | N/A | Appearance | white crystalline powder |
Safety | 16-26-36/37/39-45 | Risk Codes | 11-34 |
Molecular Structure | Hazard Symbols | F,C | |
Synonyms |
Mevalotin;Pravachol;Pravachol (TN);Pravastatine [French];1-Naphthaleneheptanoic acid,1,2,6,7,8,8a-hexahydro-a,?,6-trihydroxy- 2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,monosodium salt,(aR,?R,1S,2S,6S,8S,8aR)-;Pravastatina [Spanish];Pravastatinum [Latin];1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(R*),8aalpha))-;sodium (3R,5R)-7-[(1S,2R,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoate;1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-((2S)-2-methyl-1-oxobutoxy)-, (betaR,deltaR,1S,2S,6S,8S,8aR)-;Lipostat;SQ 31000;Paravastatin; |
Article Data | 18 |
Molecular Structure of Pravastatin sodium (CAS NO.81131-70-6):
IUPAC Name: Sodium(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
Molecular Weight: 446.50957 [g/mol]
Molecular Formula: C23H35NaO7
H-Bond Donor: 3
H-Bond Acceptor: 7
Appearance: White Crystalline Powder
Melting Point: 171.2-173 °C
storage temp.: 2-8 °C
solubility: H2O: 19 mg/mL
Flash Point: 213.2 °C
Enthalpy of Vaporization: 107.45 kJ/mol
Boiling Point: 634.5 °C at 760 mmHg
Vapour Pressure: 9.15E-19 mmHg at 25 °C
Classification Code: Antihyperlipidemic; Drug / Therapeutic Agent; Human Data
Product Categories: Active Pharmaceutical Ingredients; Antihyperlipoproteinemic; Various Metabolites and Impurities; Chiral Reagents; Intermediates & Fine Chemicals; Metabolites & Impurities; Pharmaceuticals; HMG-CoA reductase
Pravastatin sodium (CAS NO.81131-70-6) can be used as a competitive inhibitor of HMG-CoA reductase, Bioactive metabolite of Mevastatin
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | TDLo | oral | 16mg/kg/8W-I (16mg/kg) | LIVER: "JAUNDICE, CHOLESTATIC" LIVER: LIVER FUNCTION TESTS IMPAIRED SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | American Journal of Emergency Medicine. Vol. 17, Pg. 1388, 1999. |
mouse | LD50 | intravenous | 2011mg/kg (2011mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
mouse | LD50 | oral | 8939mg/kg (8939mg/kg) | SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: CHANGES IN SPLEEN | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
mouse | LD50 | subcutaneous | 2975mg/kg (2975mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
rat | LD50 | intravenous | 440mg/kg (440mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
rat | LD50 | oral | > 12gm/kg (12000mg/kg) | Yakkyoku. Pharmacy. Vol. 40, Pg. 2351, 1989. | |
rat | LD50 | subcutaneous | 3172mg/kg (3172mg/kg) | BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
rat | LDLo | intraperitoneal | 400mg/kg (400mg/kg) | Biochemistry and Molecular Biology International. Vol. 47, Pg. 519, 1999. | |
women | TDLo | oral | 16800ug/kg (16.8mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Lancet. Vol. 340, Pg. 910, 1992. |
women | TDLo | oral | 30mg/kg/21W-I (30mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)" SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | New England Journal of Medicine. Vol. 327, Pg. 649, 1992. |
Moderately toxic by intravenous and intraperitoneal. Low toxicity by ingestion. Human systemic effects. When heated to decomposition it emits acrid smoke and irritating vapors.
Safety Information of Pravastatin sodium (CAS NO.81131-70-6):
Hazard Codes: F,C
Risk Statements: 11-34
R11:Highly flammable.
R34:Causes burns.
Safety Statements: 16-26-36/37/39-45
S16:Keep away from sources of ignition.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: 3077
WGK Germany: 2
RTECS: QJ7185000
HazardClass: 9
PackingGroup: III
Pravastatin sodium (CAS NO.81131-70-6), its Synonyms are 3-beta-Hydroxycompactin sodium salt ; Aplactin ; Bristacol ; Pravachol ; Pravacol ; Pravaselect ; Pravasin ; Pravasine ; Pravastatin Natrium Mayrho Fer ; Sanaprav ; Selektine ; Selipran ; Sodium (+)-(betaR,deltaR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-hexahydro-beta,delta,6,8-tetrahydroxy-2-methyl-1-naphthaleneheptanoate, 8-((2S)-2-methylbutyrate) .